Company Profile

In October 2016, Imunetics was acquired by Oxford Immunotec Global PLC (Nasdaq:OXFD) in a cash and future payouts transaction. Immunetics Inc., a biotechnology company, works in the space of development of immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases. With a strong international presence, the firm's products include the Miniblotter instrument system for western blot, spoligotyping, and various multi-probe membrane assays; cell adhesion flow chamber for cell-cell interaction studies; and C6 peptide Lyme ELISA, a synthetic peptide ELISA test for Lyme disease anthrax. The company's products also include QuickELISA, a blood test for anthrax infection; and QualiCode western blot assays for diseases where diagnosis is challenging. In addition, it offers QuickELISA Anthrax-PA kit, an in vitro diagnostic test for the detection of antibodies to protective antigen of anthrax in human and animal samples; and BacTx Test for the bacterial contamination of platelets. In February of 2016, Immunetics announced the launch of its MycoDx™ assay for invasive fungal infections. Such infections are particularly dangerous to immunocompromised patients, including transplant recipients and those undergoing cancer therapies. MycoDx™ is a multiplex molecular assay developed by Immunetics that can identify 21 fungal pathogens in a whole blood sample.